Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.12.17

Recruiting Scientific Positions

Sai Life Sciences announces plans to recruit 500+ scientists in 2021

• Immediately initiates first phase of recruitment for 100 scientists in API process development and scale-up
• To initiate recruitment for 400 positions across Discovery Chemistry, Biology & DMPK in a phased manner over the year

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced its plans to recruit over 500 scientists during the year 2021. As the first phase of this drive, the company has initiated recruitment for scientific talent in API process and analytical research & development, particle science and engineering , niche platform technologies as well as life cycle management.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said, “Over the past 18-24 months we have been significantly augmenting our R&D facilities and rapidly growing our customer outreach. We expect these efforts to bear fruit in the coming months and are therefore looking to expand our team. This addition to our high-quality talent pool will help us better serve our customers by accelerating their projects involving complex chemistry and next generation technologies.”

As part of the current recruitment drive, the company is looking to on-board top-notch global scientific talent with M.Sc./ Ph.D / Post Doctorates in synthetic organic / analytical chemistry from reputed academic institutions, and experience in global pharma R&D of up to 20 years, across various levels. The company also has positions open for Technology Transfer focused Process Engineers and Program Managers. The full list of open positions can be viewed here.

Marking the completion of 20 years since its inception in 2019, the company announced Sai Nxt, an organisation-wide initiative aimed at transforming itself into a new generation CRO/CDMO. Guided by the insights and feedback from its customers, it committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

As part of Sai Nxt, the company has added 172 KL API & Intermediate manufacturing capacity, opened a discovery biology Lab in Cambridge, Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK and an 83,000 sq. ft. integrated research & technology facility in Hyderabad with technology platforms including flow chemistry, biocatalysis and crystallization. It became the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI). The company is now in the process of adding high potent capability in R&D and manufacturing, a new clean room block and 200KL additional manufacturing capacity.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more